Minimizing Bias When Blinding and Masking Drug Products
Summary: Overcoming complex blinding and masking challenges in clinical trials requires a balance of strategy and adaptability. When conducting clinical trials, one of the most significant dangers to success is the presence of bias, which can be minimized using appropriate blinding and masking approaches. Dr. Paul Ingram, Global Director, Strategic Development and Innovation, Clinical Supply Services at Catalent Pharma Solutions, discusses the importance of blinding treatment allocations to patients and investigators in clinical studies, as well as physically masking products that are being tested.